Edition:
United Kingdom

Hansa Medical AB (HMED.ST)

HMED.ST on Stockholm Stock Exchange

246.50SEK
18 Dec 2017
Change (% chg)

3.50kr (+1.44%)
Prev Close
243.00kr
Open
244.50kr
Day's High
248.00kr
Day's Low
244.50kr
Volume
86,359
Avg. Vol
157,140
52-wk High
271.50kr
52-wk Low
95.00kr

Latest Key Developments (Source: Significant Developments)

‍Hansa Medical Contemplates Directed Share Issue To Raise About Sek 545 mln​
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Hansa Medical Ab ::‍HANSA MEDICAL CONTEMPLATES A DIRECTED SHARE ISSUE TO RAISE APPROXIMATELY SEK 545 MILLION​.HANSA MEDICAL -COMMISSIONED EVERCORE, RBC CAPITAL AND SEB, TO INVESTIGATE POSSIBILITY OF UNDERTAKING NEW ISSUE OF SHARES TO INSTITUTIONAL INVESTORS.‍INTENDS TO USE PROCEEDS FROM DIRECTED ISSUE TO FUND CONTINUED DEVELOPMENT OF COMPANY'S EXISTING PORTFOLIO​.  Full Article

Hansa Medical Q3 operating loss up at SEK ‍​37.4 mln
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - HANSA MEDICAL AB ::Q3 OPERATING LOSS SEK ‍​37.4 MILLION VERSUS LOSS SEK 27.0 MILLION YEAR AGO.Q3 NET REVENUE SEK ‍​678,000 VERSUS SEK 0.9 MILLION YEAR AGO.  Full Article

Hansa Medical: sudden death of CEO Göran Arvidson​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - HANSA MEDICAL AB :‍ANNOUNCES SUDDEN DEATH OF CEO GÖRAN ARVIDSON​.‍CHAIRMAN ULF WIINBERG WILL SERVE AS ACTING CEO.‍BIRGIT STATTIN NORINDER WILL TAKE OVER ROLE AS CHAIRMAN OF BOARD UNTIL FURTHER NOTICE​.  Full Article

Hansa Medical: preclinical results confirm IdeS potential in cancer immunotherapy
Tuesday, 23 May 2017 

May 23 (Reuters) - HANSA MEDICAL AB :PUBLISHED PRECLINICAL RESULTS CONFIRM IDES POTENTIAL IN CANCER IMMUNOTHERAPY.PUBLISHED PRECLINICAL RESULTS CONFIRM IDES POTENTIAL IN CANCER IMMUNOTHERAPY.PUBLISHED FINDINGS DEMONSTRATE HOW PRE-TREATMENT WITH IDES IN TUMOUR ANIMAL MODELS CAN INCREASE EFFICACY OF CURRENTLY AVAILABLE ANTIBODY BASED CANCER THERAPIES.  Full Article

Hansa Medical Q2 operating loss widens to SEK 30.7 million
Thursday, 21 Jul 2016 

Hansa Medical AB : Q2 net sales 0.5 million Swedish crowns ($58,245) versus 0.5 million crowns year ago .Q2 operating loss 30.7 million crowns versus loss 22.5 million crowns year ago.  Full Article

Hansa Medical acquires UK-based Immago Biosystems Ltd
Tuesday, 19 Jul 2016 

Hansa Medical AB : Acquires United Kingdom based Immago Biosystems Ltd . Acquisition will not have a significant impact on Hansa Medical result for 2016 . Sum of acquisition was not disclosed .Immago Biosystems Ltd is a University of Oxford-spinout focused on the enhancement of antibody based cancer therapies using antibody-modulating enzymes.  Full Article

Hansa Medical: Ulf Wiinberg proposed as new Chairman
Monday, 4 Apr 2016 

Hansa Medical AB:Ulf Wiinberg proposed as new Chairman and Angelica Loskog new board member.Wiinberg was CEO of H Lundbeck A/S for several years.  Full Article

FDA clears Hansa Medical's IND application for IdeS in kidney transplantation
Monday, 4 Apr 2016 

Hansa Medical AB:US Food and Drug Administration(FDA) has completed the safety review of the company's Investigational New Drug application (IND) and has concluded that the proposed clinical investigation can proceed.Says clinical trial is scheduled to begin soon.  Full Article

Gladiator ups stake in Hansa Medical to 7.7 pct
Tuesday, 8 Mar 2016 

Finansinspektionen:Says Gladiator has increased its stake in Hansa Medical AB from 1.5 million shares to 2.5 million shares.Says Gladiator now holds 7.7 pct stake in Hansa Medical.  Full Article

Hansa Medical AB Farstorps Gard AB divests Hansa Medical shares
Tuesday, 8 Mar 2016 

Hansa Medical AB:Hansa Medical has been informed that a small group of long-term institutional investors have acquired shares from Farstorps Gard AB.Farstorps Gard AB holds about1 million shares in Hansa Medical, equivalent to about 3 percent of the number of outstanding shares in Hansa Medical.  Full Article

BRIEF-‍Hansa Medical's board has resolved on a directed share issue of SEK 545 mln​

* ‍HANSA MEDICAL'S BOARD OF DIRECTORS HAS RESOLVED ON A DIRECTED SHARE ISSUE OF SEK 545 MILLION​ Source text for Eikon: Further company coverage: